Skip to main content

Table 2 Administered agents/regimens and hazard ratio for overall survival

From: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review

Agents/regimens No. of patients No. of events, n (%) HR 95 % CI P value
Eribulin monotherapy 66 39 (59.1) 0.55 0.36–0.85 0.01*
Anthracycline-based regimen 136 120 (88.2) 1.35 1.01–1.82 0.04*
Paclitaxel monotherapy 138 103 (74.6) 1.14 0.85–1.52 0.38
Docetaxel monotherapy 79 72 (91.1) 1.30 0.95–1.79 0.10
Capecitabine monotherapy 120 100 (83.3) 0.89 0.66–1.20 0.43
Gemcitabine monotherapy 12 12 (83.3) 0.55 0.27–1.10 0.09
Vinorelbine monotherapy 37 37 (100.0) 1.15 0.76–1.73 0.51
Paclitaxel + bevacizumab 52 52 (57.7) 1.51 0.93–2.48 0.10
Docetaxel + capecitabine 30 30 (96.7) 1.13 0.74–1.73 0.57
Paclitaxel + gemcitabine 10 10 (100.0) 2.79 1.34–5.79 0.01*
  1. CI confidence interval, HR hazard ratio